News|Articles|November 20, 2026

Ruling out Rapid Relapse as Antipsychotic Withdrawal Reaction

Listen
0:00 / 0:00

Key Takeaways

  • Individual participant meta-analysis of five double-blind paliperidone relapse-prevention RCTs (LAI and oral) evaluated longitudinal PANSS trajectories preceding relapse in continuation versus placebo/discontinuation arms.
  • Discontinuation markedly increased relapse incidence (approximately 73%–74%) versus maintenance (approximately 26%–27%), confirming relapse-prevention efficacy across formulations in clinically stable patients.
SHOW MORE

A study of schizophrenia relapse considers preceding symptoms, if presentation differs with ongoing or discontinued antipsychotic, and whether rapid relapse could represent antipsychotic withdrawal.

Relapse of schizophrenia symptoms after initiating a new antipsychotic is characterized as either rapid or delayed by investigators who found the rapid presentation more likely with higher baseline symptom severity.1

Krisya Louie, MSc, of the department of psychiatry, University of Oxford, and colleagues also found rapid relapse occurring in the same proportion of those maintained on, as having discontinued their antipsychotic. That rapid relapse is not overrepresented in the discontinuation group suggests, the investigators reason, that it is not an antipsychotic withdrawal reaction.

Louie, et al conducted a meta-analysis of randomized controlled trials (RCTs) which had compared courses of illness and relapse in those maintained on active treatment or switched to placebo/discontinuation arm. The investigators describe the study as the first to characterize and compare longitudinal symptom trajectories preceding relapse across antipsychotic continuation and discontinuation groups.

"Current guidance endorses individualized treatment management strategies that balance relapse risk against tolerability," Louie and colleagues observe. "However, there remains a paucity of methodologically robust evidence to guide clinicians on how best to discontinue antipsychotics, how relapse should be monitored during discontinuation, and whether particular symptom patterns increase risk of relapse."

RCTs eligible for inclusion in the meta-analysis were double-blind, placebo-controlled relapse-prevention evaluations of antipsychotic treatment with participants clinically stable for more than 3 months before randomly assigned to placebo (discontinuation) or continued treatment arms.

The investigators identified 5 eligible trials, all of which assessed discontinuation of paliperidone, either as long-acting injectable (LAI) or oral formulation. The meta-analysis cohort comprised 417 participants experiencing relapse during the double-blind, post-randomization phase. The mean baseline total Positive and Negative Syndrome Scale (PANSS) score was 54.8 in the LAI trials and 52.9 with the oral dosage form. Relapse rates were, as expected, higher in the discontinuation group: 73% with LAI and 74% with oral treatment discontinuation compared to 27% with continued LAI and 26% with continued oral.

Rapid relapse in the LAI trials represented 20% (39 of 197) of relapses occurring in the discontinuation group, not a statistically significantly different proportion than the 11% (8 of 74) with continued active treatment. With oral dosage, 27% (29 of 108) of relapses were rapid in the discontinuation group, and in 26% (10 of 38) with continued treatment.

In both the LAI and oral dose trials, those manifesting rapid relapse had significantly higher PANSS scores at the time of relapse than those with delayed relapse trajectory.In the LAI cohorts, all PANSS items were significantly higher in those with rapid relapse, except 3 general psychopathology subscale items which were nonsignificant after correction for false discovery rate. In the oral dose trials, those with rapid relapse had significantly more severe symptoms in 20 PANSS items, with 10 non-significant after correction.

"The strongest predictor of rapid trajectory membership was baseline symptom severity, with higher baseline PANSS scores associated with rapid relapse in multivariable analyses adjusting for study, treatment group, sex, and age," the investigators indicate.

Rapid Relapse: Illness Reemergence, not Drug Withdrawal

Louie, et al indicate that rapid relapse occurring in the same proportion of those experiencing relapse with ongoing or upon discontinuing antipsychotic treatment is consistent with other evidence that it represents reemergence of illness rather than an antipsychotic withdrawal reaction.

"Our findings complement previous work showing that relapse risk is not associated with rate of receptor occupancy decline, but increases once D2 blockade falls below threshold," indicated Louie et al.2 The investigators also cite studies which have found no difference in relapse risk between abrupt and gradual discontinuation, or with different tapering speeds.

Rajeev Krishnadas, MD, PhD, University of Cambridge, and CA Smitha, MD, Government Medical College, concur in accompanying commentary, indicating that "these findings challenge the assumption that rapid deterioration on stopping antipsychotics is necessarily a medication discontinuation effect." 3

They note the clinical importance of the distinction: if rapid relapse is a discontinuation effect, slower tapering would be warranted when medication change is required.Mislabeling rapid relapse as a discontinuation effect, they caution, can lead to poor management.

"Put simply, reemergence of psychosis is unlikely to represent a simple antipsychotic discontinuation effect, but reflects the complex pathophysiology of the disorder.The effect likely represents the persistence of the preexisting susceptibility to psychosis that is not addressed by existing treatments," Krishnadas and Smitha suggest.

Dr Bender reports on medical innovations and advances in practice and edits presentations for news and professional education publications. He previously taught and mentored pharmacy and medical students, and he provided and managed pharmacy care and drug information services.

References

1. Louie K, Jauhar S, Rubio J, et al. Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis. Lancet Psychiatry. 2026; 13:829-840.

2. McCutcheon RA, Taylor D, Rubio J, et al. Does slow and steady win the race? Rates of antipsychotic discontinuation, antipsychotic dose, and risk of psychotic relapse. Schizophr Bull. 2024; 50:513-520.

3. Krishnadas R, Smith CA. Relapse or rebound: The case for personalization in antipsychotic discontinuation. Lancet Psychiatry. 2026; 13:812-813.


Related to this article